RESUMEN
@#AIM: To observe the efficacy of two conbercept regimens in the treatment of polypoid choroidal angiopathy.<p>METHODS: Twenty-one patients with polypoidal choroidal vasculopathy who met the inclusion criteria and were treated in our hospital were randomly divided into two groups. The group A(9 patients and 9 eyes)was treated with 3+Q12W scheme, namely, 0.5mg conbercept ophthalmic injection was intravitreally injected every 4wk for 3 consecutive times, and then 1 time every 12wk. In the group B(12 patients and 12 eyes), 3+TAE scheme was carried out, that is 0.5mg conbercept ophthalmic injection was intravitreally injected every 4wks for 3 consecutive times. The time of next injection was determined according to the evaluation results of each visit. The interval to the next visit/treatment was ≥ 4wk and ≤ 12wk. The best corrected visual acuity(BCVA), central retinal thickness(CRT)and the frequency of injection were compared between the two groups at 12 and 48wk after treatment, respectively.<p>RESULTS: BCVA of the group A was 74.78±11.23 letters and 74.67±13.94 letters at 12 and 48wk after treatment, which increased by 7.00±4.21 letters and 6.89±4.48 letters at the baseline before treatment, respectively. BCVA in the group B was 77.83±5.46 letters and 77.58±8.59 letters respectively at 12 and 48wk after treatment, which were 8.75±7.54 letters and 8.50±5.60 letters higher than the baseline before treatment. At the 12 and 48wk after injection, the average CRT in the group A was 276.33±44.34μm and 240.56±40.11μm, respectively, which were 43.22±42.21μm and 79.00±53.64μm lower than the baseline before treatment. At the 12 and 48wk after injection, the average CRT in the group B was 271.58±63.08μm and 241.00±43.91 μm, which were 57.42±45.33μm and 88.00±61.16μm lower than the baseline before treatment, respectively. The average times of intravitreal injection of conbercept were 6.00±0.00 and 7.75±1.14 times in the 3+Q12W group and the 3+TAE group, respectively.<p>CONCLUSION: Two different regimens of conbercept could reduce the CRT and improve the visual acuity of the patients with polypoidal choroidal vasculopathy. And the times of intravitreal injection in the 3+Q12W administration group were less than those in the3+TAE administration group.
RESUMEN
@#AIM: To explore the levels of interleukin-8, interleukin-8 receptor 1, 2(CXCR1, CXCR2)in aqueous humor of polypoid choroidal vasculopathy(PCV)and their clinical significance.<p>METHODS: Totally 67 patients with PCV in our hospital were selected as PCV group, and another 50 patients with cataract were selected as control group, fluorescence quantitative PCR(QPCR)was used to detect the expression of IL-8, CXCR1 and CXCR2 mRNAs in aqueous humor of two groups, the best corrected visual acuity(BCVA)of all subjects were measured by the international standard visual acuity chart, optical coherence tomography(OCT)was used to detect foveal retinal thickness(CMT), the receiver operating characteristic curve(ROC)was created to analyze the predictive values of IL-8, CXCR1 and CXCR2 in the occurrence of PCV. Multivariate Logistic regression analysis was used to assess the risk factors for PCV.<p>RESULTS: Compared with the control group, the expression of IL-8, CXCR1 and CXCR2 mRNA increased in group PCV. BCVA in PCV group decreased and CMT increased(<i>P</i><0.05). IL-8, CXCR1 and CXCR2 were significantly positively correlated with BCVA(<i>r</i>=0.438, 0.346, 0.385, all <i>P</i><0.05), IL-8, CXCR1 and CXCR2 were positively correlated with CMT(<i>r</i>=0.378, 0.606, 0.357, all <i>P</i><0.05). Logistic multivariate regression analysis showed that IL-8, CXCR1, CXCR2, BCVA and CMT were the risk factors of PCV. The AUC of IL-8, CXCR1 and CXCR2 for PCV diagnosis was 0.882, 0.860 and 0.812.<p>CONCLUSION: The expression of IL-8, CXCR1 and CXCR2 in PCV aqueous humor were all increased, which was not only related to BCVA and CMT in patients, but also related to the occurrence of PCV, and it may become a potential predictor of PCV.